EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Quantitative Medicine to Support Drug Development and Regulatory Decisions: A UK Regulatory Approach Informed by ICH M15

Essam Kerwash iD, Andrew S Butler iD, Maria Malamatari iD, Susan Cole iD

Clinical and Translational Science · 2026-06 · 19 (6)

DOI: 10.1111/cts.70636 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 13.06.2026. Verfasst von Essam Kerwash und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK. Hauptthemen laut MEDLINE: Drug Development. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Quantitative medicine supports modern drug development and regulatory decision‐making by integrating non‐clinical and clinical data to inform dose selection, trial optimization, and extrapolation across populations and benefit–risk assessment. The Medicines and Healthcare products Regulatory Agency (MHRA) has adopted quantitative approaches across the product lifecycle within a risk‐proportionate regulatory framework. Internationally, the ICH M15 guideline provides a harmonized framework for planning, evaluation and documentation of model‐informed drug development (MIDD) evidence which is aligned with MHRA practice. This perspective describes the application of quantitative medicine to UK regulatory decision‐making using two case studies: sugemalimab (Eqjubi) in oncology and lecanemab (Leqembi) in Alzheimer's disease. The case studies are assessed using ICH M15 concepts, including context of use, model influence, and consequence of a wrong decision. For sugemalimab, quantitative pharmacokinetic modeling supported a high‐impact dosing decision with clinically meaningful consequences of a wrong decision requiring proportionate scrutiny and mitigation of uncertainty. For lecanemab, multiple quantitative models with lower individual influence supported interpretation of pharmacokinetic variability, biomarkers, and clinical outcomes within the overall benefit–risk assessment. These case studies demonstrate how quantitative models can support decisions with differential impact ranging from critical dosing decisions to interpretation of complex data. Regulatory policy that is aligned with ICH M15 can be used to support the use of quantitative medicine to link complex modeling approaches with regulatory decision‐making and enable patient access to medicines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentHumansUnited KingdomRisk AssessmentAlzheimer DiseaseAntibodies, Monoclonal, HumanizedDrug ApprovalDecision Making

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK.

ORCID-Profile: Essam Kerwash, Andrew S Butler, Maria Malamatari, Susan Cole

Zitieren

APA

Kerwash, E., Butler, A. S., Malamatari, M., & Cole, S. (2026). Quantitative Medicine to Support Drug Development and Regulatory Decisions: A UK Regulatory Approach Informed by ICH M15. Clinical and Translational Science, 19(6). https://doi.org/10.1111/cts.70636

Vancouver

Kerwash E, Butler AS, Malamatari M, Cole S. Quantitative Medicine to Support Drug Development and Regulatory Decisions: A UK Regulatory Approach Informed by ICH M15. Clinical and Translational Science. 2026;19(6). doi:10.1111/cts.70636

BibTeX
@article{Kerwash2026,
  author = {Kerwash, Essam and Butler, Andrew S and Malamatari, Maria and Cole, Susan},
  title = {Quantitative Medicine to Support Drug Development and Regulatory Decisions: A UK Regulatory Approach Informed by ICH M15},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {6},
  doi = {10.1111/cts.70636}
}
Kostenlos starten →